Výsledky vyhledávání - "DANIEL SCHLAUCH"

Akademický článek

Determinants of Surgical Outcomes in Tricuspid Valve Endocarditis

Autor: Jeffrey P. Steinhoff, MD, Sahiti Kolli, MS, Meredith P. Mattlin, MA, Daniel Schlauch, PhD, Andrew T. Braisted, MHSA, Sreenath V. Reddy, MD, Charles Klodell, MD, Todd Dewey, MD, Gregory P. Fontana, MD

Publikováno v: Annals of Thoracic Surgery Short Reports, Vol 2, Iss 3, Pp 347-350 (2024)

Background: Current treatment guidelines for infective endocarditis focus on left-sided infective endocarditis. Because right-sided infective endocarditis has different presentations and outcomes, it is crucial to further delineate surgical outcomes

Externí odkaz: https://doaj.org/article/36a36d06d81148aa92061a6b6c988949

Zobrazit plný text záznamu

Akademický článek

The Network Zoo: a multilingual package for the inference and analysis of gene regulatory networks

Publikováno v: Genome Biology, Vol 24, Iss 1, Pp 1-23 (2023)

Abstract Inference and analysis of gene regulatory networks (GRNs) require software that integrates multi-omic data from various sources. The Network Zoo (netZoo; netzoo.github.io) is a collection of open-source methods to infer GRNs, conduct differe

Externí odkaz: https://doaj.org/article/01292b2a2c0c4ab587bb305ea80549fe

Zobrazit plný text záznamu

Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics

Autor: Denise A. Yardley, Carissa Jones, Daniel Schlauch, David R. Spigel, Rebecca Lachs, Erika Hamilton, Andrew J. McKenzie, Howard A. Burris, Emma Sturgill, Mythili Shastry, Amanda Misch, Suzanne F. Jones

Publikováno v: JCO Precision Oncology. :1297-1311

PURPOSE Molecular biomarkers informing disease diagnosis, prognosis, and treatment decisions in patients with breast cancer are being uncovered by next-generation sequencing (NGS) technologies. In this study, we survey how NGS is used for patients wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08da20d1fef52a7400b706a06069d12f
https://doi.org/10.1200/po.20.00469

Zobrazit plný text záznamu

Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors

Autor: Suzanne F. Jones, James A. Reeves, David R. Spigel, Howard A. Burris, Andrew J. McKenzie, Daniel Schlauch, Xiaotong Fu

Publikováno v: JCO Precision Oncology. :1625-1638

PURPOSE Next-generation sequencing (NGS) testing is being incorporated into routine standard of care for patients with cancer. Immune checkpoint inhibitors (CPIs) are approved for use in both tumor-specific and tumor-agnostic indications. We sought t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a76cc75d02c51df14f4f426a0382755f
https://doi.org/10.1200/po.21.00008

Zobrazit plný text záznamu

Abstract PS18-34: Physician adoption and molecular landscape of next-generation sequencing in breast cancer patients from community-based clinics

Autor: Rebecca Lachs, Carissa Jones, Erika Hamilton, Andrew J. McKenzie, Mythili Shastry, Amanda Misch, Emma Sturgill, Suzanne F. Jones, Denise A. Yardley, David R. Spigel, Daniel Schlauch, Howard A. Burris

Publikováno v: Cancer Research. 81:PS18-34

Background: Molecular biomarkers such as the expression status of hormone receptors (HR) and HER2 influence disease diagnosis, prognosis, and treatment decisions in breast cancer patients. Recent advances in genetic sequencing technologies and target

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::31eb69064eb6a19bbaaed1a5d85ae963
https://doi.org/10.1158/1538-7445.sabcs20-ps18-34

Zobrazit plný text záznamu

Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19

Autor: Marjorie Wongskhaluang, Angela Junglen, Charles F. LeMaistre, Joseph S.A. Restivo, Gregg Fromell, Shanna A. Arnold Egloff, Lindsay E. Sears, Howard A. Burris, Pratik Doshi, Mick Correll, Daniel Schlauch, Casey Martin

Publikováno v: J Clin Invest

BACKGROUND: Evidence supporting convalescent plasma (CP), one of the first investigational treatments for coronavirus disease 2019 (COVID-19), has been inconclusive, leading to conflicting recommendations. The primary objective was to perform a compa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07bf7f35d01190b1d47085b4b984a45b
https://doi.org/10.1172/jci151788

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání